GREY:ICOTF - Post by User
Post by
curtismilleron Jun 21, 2018 8:42pm
94 Views
Post# 28209846
amphotericin B - 500 million in sales -2014
amphotericin B - 500 million in sales -2014 In 2013, Pfizer (PFE) reported $775 million in sales of voriconazole (Vfend®),
while Merck (MRK) reported $309 million in sales of posaconazole (Noxafil®).
Pfizer's Diflucan® (fluconazole), now available as a generic, reported peak sales of $1.17 billion in 2003. In 2013, Merck reported $660 million in sales of caspofungin (Cancidas®) while Astellas reported $307 million in sales of micafungin (Mycamine®). These are less effective drugs with usage far greater than AmB due to the fact that they are much less toxic
This is a game changer.....read article.
.https://www.talkmarkets.com/content/stocks--equities/matinas-mat2203-could-be-a-game-changer?post=111761&page=3